Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...

Edwards Lifesciences recently announced it would report its first-quarter 2026 results on April 23, with early commentary ...

Edwards Lifesciences revealed that its Q1 2026 performance was better than expected, prompting it to uplift its previous FY26 outlook.

The stronger outlook follows mixed results from other major medical device makers in the latest quarter, after both Abbott ...

Fri, February 6, 2026 at 1:15 PM UTC Edwards delivered $1.55 billion in Q3 2025 revenue, beating estimates by $50 million. The company's TAVR franchise continues dominating a market Edwards helped ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

Edwards LifesciencesEW stock wavered Wednesday before closing in the green after the heart-valve replacement maker issued a bullish outlook for 2026. The medtech company makes nonsurgical replacements ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

Analysts expect Edwards to post earnings of 73 cents per share on revenue of $1.6 billion, representing year-over-year growth of 17.6% and 13.48% respectively. That would mark a sequential improvement ...

Edwards Lifesciences Corp., of Irvine, Calif., petitioned the Centers for Medicare & Medicaid Services to revise the Medicare coverage policy for transcatheter aortic valve replacement (TAVR) devices ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...

Edwards Lifesciences (EW) grew TAVR sales 12.4% to $1.15B while Boston Scientific (BSX) exited TAVR entirely for cardiovascular diversification. Boston Scientific’s operating income surged 384.5% to ...